Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Xiongwen Yang
Bo Yang
Dan Li
Wei Pan
Qin Tong
Lili Wang
Danjun Chen
Chengxiao Fu
机构：
[1] Hengyang Medical School,Department of Pharmacy, The First Affiliated Hospital
[2] University of South China,Institute of Pharmacy and Pharmacology, College of Basic Medical Science, Hengyang Medical School
[3] University of South China,Clinical Pharmacology Research Center, The First Affiliated Hospital
[4] Hengyang Medical School,Department of Oncology, The First Affiliated Hospital
[5] University of South China,undefined
[6] Hengyang Medical School,undefined
[7] University of South China,undefined
来源：
Clinical Drug Investigation | 2024年 / 44卷 / 3期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：199 / 207
页数：8
相关论文
共 50 条
  • [21] Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Sharma, Priyanka
    Gupta, Sheeba Varghese
    Bhatt, Priyanka
    Kandukuru, Abhishek
    Cheng, Feng
    Upadhyay, Gunjan
    Sutariya, Vijaykumar
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (12) : 720 - 728
  • [22] Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)
    Li, Bing
    Chen, Yan
    Zhang, Yongyi
    Qian, Mengying
    Shan, Qing
    Qian, Jiao
    Guo, Jinmin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [23] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [24] Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database
    Shan, Huifang
    Wei, Chunyan
    Zhang, Jingyi
    Wu, Bin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [25] A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)
    Huang, Min
    Li, Peng
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2025, 317 (01)
  • [26] A REALWORLD PHARMACOVIGILANCE STUDY OF FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) EVENTS FOR EMPAGLIFLOZIN AND DAPAGLIFLOZIN
    Milutinovic, Stefan
    Petrovic, Marija
    Jancic, Predrag
    Trajkovic, Hristina
    Alarcon, Ricardo Orlando Escarcega
    Chazal, Richard A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 319 - 319
  • [27] Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
    Sato, Kenichiro
    Mano, Tatsuo
    Iwata, Atsushi
    Toda, Tatsushi
    BIOSCIENCE TRENDS, 2020, 14 (02) : 139 - 143
  • [28] CARDIOTOXIC EFFECTS OF BTK INHIBITORS : PHARMACOVIGILANCE ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Patel, Sagar
    Pandya, Krutarth K. K.
    Raval, Maharshi
    Patel, Akanksha
    Trivedi, Jaahnavee
    Patel, Riya
    Titus, Anoop
    Sattar, Yasar
    Victor, Varun
    Alraies, M. Chadi
    Bhakta, Shyam
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2390 - 2390
  • [29] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [30] Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Ma, Pan
    Pan, Xinmei
    Liu, Ruixiang
    Qu, Ya
    Xie, Linli
    Xie, Jiangchuan
    Cao, Liya
    Chen, Yongchuan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345